IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings (IQV – Research Report). The ...

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

Lupin receives tentative USFDA approval for its generic HIV treatment, combining Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. The drug, equivalent to Janssen's Symtuza, has ...

IQVIA Holdings Inc. closed 22.27% below its 52-week high of $261.73, which the company achieved on March 8th.

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Dynamic Advisor Solutions LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 9.1% in the ...